| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Defb6 |
| Uniprot No | Q91VD6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-63aa |
| 氨基酸序列 | QLINSPVTCMSYGGSCQRSCNGGFRLGGHCGHPKIRCCRRK |
| 预测分子量 | 19.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Defb6重组蛋白的3篇参考文献及其摘要概括：
1. **《Recombinant human beta-defensin 6 contributes to host defense against Pseudomonas aeruginosa》**
- 作者：Yang D, et al.
- 摘要：研究通过重组表达人源Defb6蛋白，证明其在体外和动物模型中显著抑制铜绿假单胞菌感染，并揭示了其通过破坏细菌膜结构和激活免疫信号通路发挥抗菌作用。
2. **《Expression and functional characterization of murine Defb6 in mucosal immunity》**
- 作者：Li X, et al.
- 摘要：构建小鼠Defb6重组蛋白，发现其在小肠上皮细胞中高表达，通过体外实验证实其广谱抗菌活性，并证明其通过TLR4/NF-κB通路增强肠道屏障功能。
3. **《Structural analysis and therapeutic potential of DEFB6 in diabetic wound healing》**
- 作者：Wang H, et al.
- 摘要：通过大肠杆菌系统高效表达DEFB6重组蛋白，解析其三维结构，并在糖尿病小鼠伤口模型中证实其通过促进角质形成细胞迁移和抑制耐药菌感染加速创面愈合。
注：以上文献信息为示例性质，实际引用需以具体文献内容为准。建议通过PubMed或Web of Science以“DEFB6 recombinant”或“Defensin beta 6 expression”为关键词检索最新研究。
Defb6. also known as beta-defensin 6. is a small cationic peptide belonging to the defensin family, which plays a critical role in innate immunity. These evolutionarily conserved proteins are characterized by their antimicrobial activity against bacteria, fungi, and viruses. Defensins are typically produced by epithelial cells and immune cells, serving as a first-line defense at mucosal surfaces. Defb6 is encoded by the DEFB6 gene in humans and is distinguished by its six conserved cysteine residues that form three intramolecular disulfide bonds, stabilizing its β-sheet-rich structure.
Recombinant Defb6 protein is generated through biotechnological methods, often using bacterial (e.g., E. coli) or mammalian expression systems. The recombinant form retains the functional properties of the native peptide, including its ability to disrupt microbial membranes via electrostatic interactions and its immunomodulatory functions, such as chemotaxis for immune cells. Research highlights its role in maintaining gut microbiota balance, protecting against enteric pathogens, and modulating inflammatory responses. Dysregulation of Defb6 has been implicated in diseases like inflammatory bowel disease (IBD) and colorectal cancer, underscoring its therapeutic potential.
Recent studies explore Defb6's applications beyond infection control, including wound healing, vaccine adjuvants, and cancer immunotherapy. Challenges in its clinical translation include susceptibility to proteolytic degradation and optimizing delivery systems. Ongoing efforts focus on engineering stabilized analogs and nanoformulations to enhance bioavailability. Defb6's dual role as an antimicrobial and immune regulator positions it as a promising candidate for multifunctional therapeutics in infectious and inflammatory diseases.
×
